RECRUITING

ASF Alport Syndrome Registry

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Alport Syndrome Foundation's (ASF's) Alport Patient Registry (the Registry) is open to individuals living with Alport syndrome in the United States (US) and US territories and outlying islands. The Registry welcomes participants of all ages who have a confirmed clinical diagnosis of Alport syndrome. A confirmed diagnosis could be obtained via genetic testing, biopsy, and/or from a medical professional's clinical assessment of the individual's symptoms and/or family history. Participants can have any form and stage of this disease to be eligible for inclusion in the Registry. Patient participation in the Registry is crucial to helping attract and advance research, understanding understudied aspects of the disease, and informing clinical trials that may lead to Alport syndrome therapies and/or a cure. The Registry is accessed through a secure, online application. Participants report their own health history in the Registry and are encouraged to update any changes, at most, every three months. The security of each participant's information is a top priority. Any detail that could identify an individual participant is kept confidential in the Registry and such data are de-identified to protect the participant's privacy. No electronic health records or social security numbers are requested by or connected to the Registry. A parent or legal guardian may consent to enroll a child/dren Alport patient(s) under the age of 18 years. An additional assent form is used for individuals ages 7-17. At age 18, participants will be required to re-consent as an adult if they choose to continue to participate in the Registry.

Official Title

Alport Syndrome Foundation Alport Syndrome Registry

Quick Facts

Study Start:2023-08-24
Study Completion:2048-08-23
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06526741

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:0 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Confirmed diagnosis of Alport syndrome by a certified genetic counselor, treating physician or nephrologist.
  2. 2. Signed informed consent/assent must be provided by the subject and/or caregiver (parent/legal guardian) including compliance with the restrictions listed in the informed consent/assent form and in the study protocol. (Separate age-appropriate assent forms are provided for ages 7-12 years and ages 13-17 years.)
  3. 3. Must reside in the USA or US territories and outlying islands. (This criterium may change at an as-yet undetermined future date.)
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Benjamin A Weinstock, PhD
CONTACT
5155560699
aweinstock@alportsyndrome.org
Lisa Bonebrake
CONTACT
6199873522
lbonebrake@alportsyndrome.org

Principal Investigator

Benjamin A Weinstock, PhD
PRINCIPAL_INVESTIGATOR
Alport Syndrome Foundation

Study Locations (Sites)

On-line only: https://asfalportpatientregistry.healthie.net
Scottsdale, Arizona, 85261
United States

Collaborators and Investigators

Sponsor: Alport Syndrome Foundation

  • Benjamin A Weinstock, PhD, PRINCIPAL_INVESTIGATOR, Alport Syndrome Foundation

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-08-24
Study Completion Date2048-08-23

Study Record Updates

Study Start Date2023-08-24
Study Completion Date2048-08-23

Terms related to this study

Keywords Provided by Researchers

  • Alport
  • COL4A3
  • COL4A4
  • COL4A5
  • Collagen Type-IV
  • Glomerulonephropathy
  • Glomerulosclerosis
  • Genetic Kidney Disease

Additional Relevant MeSH Terms

  • Alport Syndrome
  • Thin Basement Membrane Disease
  • Hereditary Nephritis